Skip to main content
. 2019 Nov 15;116(49):24583–24592. doi: 10.1073/pnas.1911393116

Fig. 6.

Fig. 6.

OSI-027 reduces human RMS cell-derived xenograft tumor growth by inducing macropinocytosis. (A) Line graph showing the inhibitory effects of OSI-027 (150 mg/kg orally, 3 times/wk, starting at 1 d after tumor cell grafting) on the tumor volume of RD and RH30 cell-derived xenograft tumors (n = 5/group). *P < 0.05; **P < 0.01 compared with vehicle-treated controls. (B) Hematoxylin and eosin staining of the 5-µm sections of tumors derived from xenografted RD cells (Left) and RH30 cells (Right) harvested on day 33 and day 21, respectively. Arrowheads denote vacuolated and ruptured cells. (C and D) Immunofluorescence staining of LAMP-1 and EEA1 in the tumor sections of vehicle- or OSI-027–treated RD (C) and RH30 (D) cell-derived xenografts. (Magnification: A, C, and D, 400×.) Photographs were captured using an Olympus BX51 microscope.